Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

Blood

Volumn 98, Issue 8, 2001, Pages 2319-2325

  Leporrier, Michel ^a   Chevret, Sylvie ^a   Cazin, Bruno ^a   Boudjerra, Najda ^a   Feugier, Pierre ^a   Desablens, Bernard ^a   Rapp, Marie José ^a   Jaubert, Jerome ^a   Autrand, Claudie ^a   Divine, Marine ^a   Dreyfus, Brigitte ^a   Maloum, Karim ^a   Travade, Philippe ^a   Dighiero, Guillaume ^a   Binet, Jacques Louis ^a   Chastang, Claude ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE PHOSPHATE; PREDNISONE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; APLASIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEMOLYTIC ANEMIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HAIR LOSS; HUMAN; INCIDENCE; INFECTION; LEUKEMIA REMISSION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0035889147     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.8.2319     Document Type: Article

References (35)

1. Binet J, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.
2. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med. 1998;338:1506-1514.
3. French Cooperative Group on CLL. Effectiveness of "CHOP" regimen in advanced untreated chronic lymphocytic leukemia. Lancet. 1986;i:1346-1349.
4. French Cooperative Group on CLL, Long-term results of the CHOP regimen in stage C chronic lymphocytic leukemia. Br J Haematol. 1989;73:334-340.
5. French Cooperative Group on Chronic Lymphocytic Leukemia. Is the ChOP regimen a good treatment for advanced CLL? Results from two randomised clinical trials. Leuk Lymphoma. 1994:13;449-456.
6. French Cooperative Group on CLL. A randomised clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood. 1990;75:1422-1425.
7. Hansen MM, Andersen E, Birgens H, et al. CHOP versus chlorambucil/prednisone in chronic lymphocytic leukemia. Leuk Lymphoma. 1991;5(suppl 1):97-100.
8. Kimby E, Mellstedt H. Chlorambucil/prednisone versus CHOP in symptomatic chronic lymphocytic leukemia of B-cell type, A randomised trial. Leuk Lymphoma. 1991;5(suppl 1):93-96.
9. Keating MJ, Scouros, M, Murphy S, et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukaemia. 1988;2:157-164.
10. Keating MJ, Hester JP, McCredie KB, Burgess MA, Murphy WK, Freireich FJ. Long term results of CAP therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 1990;2:391-397.
11. Grever MR, Kopecky KJ, Colman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hématol. 1988;30:457-459.
12. Keating MJ, Kantarjian M, Redman J, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74:19-25.
13. Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol. 1990;17(suppl 8):49-62.
14. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol. 1990;17 (suppl 8):3-17.
15. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine monophosphate. A synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol. 1991;9:175-188.
16. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993;82:1695-1700.
17. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs. 1997;53:1005-1037.
18. Keating MJ, O'Brien S, Lerner S, et al. Long term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165-1171.
19. French Cooperative Group on CLL, Johnson S, Smith JS, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet. 1996;347:1432-1438.
20. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
21. International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria. Ann Intern Med. 1989;110:236-239.
22. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
23. Maloum K, Pritsch O, Dighiero G. Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement. Hematol Cell Ther. 1997;39:1-6.
24. World Health Organization. WHO handbook for reporting results of cancer treatment. Albany, NY: WHO Publications; 1979.
25. George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis. 1974;27:15-24.
26. Jaksic B, Delmer A, Brugiatelli M, et al. Fludarabine vs. high dose continuous chlorambucil: interim analysis of a randomised phase II study in untreated B-cell chronic lymphocytic leukemia [abstract]. Blood. 1996;88(suppl 1):588a.
27. Keating MJ, O'Brien S, Kantarjian H, et al. Long term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993;81:2878-2884.
28. Saven A, Lemon RH, Kosty M, Beutler E, Piro L. 2-Chlorodesoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995;13:570-574.
29. Delannoy A, Martiat P, Gala JL, et al. 2-Chlorodesoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukaemia. 1995;9:1130-1135.
30. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000;96:2723-2729.
31. Byrd JC, Hargis JB, Kester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995;49:135-142.
32. Busutil DP, Chasty RC, Copplestone JA, Hamon MD, Prentice AG. Infections complicating treatment of lymphoid malignancies with fludarabine [letter]. Br J Hematol. 1996;93(suppl 1):69.
33. Anaissie EJ, Kotoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559-566.
34. Myint H, Copplestone JA, Orchard J, et al. Fludarabine - related autoimmune hemolytic anaemia in patients with chronic lymphocytic leukemia. Br J Hematol. 1995;91:342-344.
35. Weiss RB, Freiman J, Kweder S, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol. 1998;16:1885-1889.